Related Experiment Video

Updated: Jan 13, 2026

Author Spotlight: Investigating the Pathophysiology of Eosinophilic Esophagitis
03:23

Author Spotlight: Investigating the Pathophysiology of Eosinophilic Esophagitis

Published on: May 10, 2024

1.3K

Rituximab and Intravenous Immunoglobulin (IVIG) for Refractory Eosinophilic Fasciitis: A Case Report

Maryam Sahebari1, Motahhareh Karimoddini2, Naser Tayyebi Meibodi3

  • 1Rheumatic Diseases Research Center, Mashhad University of Medical Sciences Mashhad Iran.

Clinical Case Reports
|January 7, 2026
PubMed

Eosinophilic fasciitis (EF) is a rare condition with an unknown cause. This case study showed that a 40-year-old man with EF did not respond to standard treatments but improved after receiving rituximab and intravenous immunoglobulin (IVIG). Further studies are needed to confirm rituximab's effectiveness and long-term safety for EF.

Keywords:
eosinophilic fasciitisintravenous immunoglobulinrefractory eosinophilic fasciitisrituximab

Related Concept Videos

Myocarditis III: Medical Management01:14

Myocarditis III: Medical Management

Myocarditis: Comprehensive Medical ManagementMyocarditis, the heart muscle inflammation, requires a comprehensive medical management strategy that addresses the underlying cause, provides supportive care, manages symptoms, and reduces cardiac workload.Infections and Autoimmune CausesAdminister appropriate antimicrobial therapy when an infectious agent causes myocarditis. For instance, penicillin treats infections caused by Group A Streptococcus. In cases where autoimmune processes are...
168